Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-312024-04-01falseNo description of principal activity1216truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 11680825 2024-04-01 2025-03-31 11680825 2023-04-01 2024-03-31 11680825 2025-03-31 11680825 2024-03-31 11680825 c:Director1 2024-04-01 2025-03-31 11680825 d:Buildings 2024-04-01 2025-03-31 11680825 d:Buildings 2025-03-31 11680825 d:Buildings 2024-03-31 11680825 d:Buildings d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 11680825 d:PlantMachinery 2024-04-01 2025-03-31 11680825 d:PlantMachinery 2025-03-31 11680825 d:PlantMachinery 2024-03-31 11680825 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 11680825 d:MotorVehicles 2024-04-01 2025-03-31 11680825 d:MotorVehicles 2025-03-31 11680825 d:MotorVehicles 2024-03-31 11680825 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 11680825 d:FurnitureFittings 2024-04-01 2025-03-31 11680825 d:FurnitureFittings 2025-03-31 11680825 d:FurnitureFittings 2024-03-31 11680825 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 11680825 d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 11680825 d:CurrentFinancialInstruments 2025-03-31 11680825 d:CurrentFinancialInstruments 2024-03-31 11680825 d:Non-currentFinancialInstruments 2025-03-31 11680825 d:Non-currentFinancialInstruments 2024-03-31 11680825 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 11680825 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 11680825 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 11680825 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 11680825 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-03-31 11680825 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-03-31 11680825 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-03-31 11680825 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-03-31 11680825 d:ShareCapital 2025-03-31 11680825 d:ShareCapital 2024-03-31 11680825 d:RetainedEarningsAccumulatedLosses 2025-03-31 11680825 d:RetainedEarningsAccumulatedLosses 2024-03-31 11680825 c:FRS102 2024-04-01 2025-03-31 11680825 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 11680825 c:FullAccounts 2024-04-01 2025-03-31 11680825 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11680825 6 2024-04-01 2025-03-31 11680825 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure

Registered number: 11680825









AMG PHARMACEUTICALS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

 
AMG PHARMACEUTICALS LIMITED
REGISTERED NUMBER: 11680825

BALANCE SHEET
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
571,322
654,793

Investments
 5 
237,554
237,554

  
808,876
892,347

Current assets
  

Stocks
  
1,099,591
746,748

Debtors: amounts falling due within one year
 6 
1,080,945
1,326,792

Cash at bank and in hand
 7 
243,923
116,009

  
2,424,459
2,189,549

Creditors: amounts falling due within one year
 8 
(2,037,478)
(1,920,924)

Net current assets
  
 
 
386,981
 
 
268,625

Total assets less current liabilities
  
1,195,857
1,160,972

Creditors: amounts falling due after more than one year
 9 
(141,537)
(189,898)

  

Net assets
  
1,054,320
971,074


Capital and reserves
  

Called up share capital 
  
2
2

Profit and loss account
  
1,054,318
971,072

  
1,054,320
971,074


Page 1

 
AMG PHARMACEUTICALS LIMITED
REGISTERED NUMBER: 11680825
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 1 December 2025.




C S Bhandal
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

AMG Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
The presentation currency of the financial statements is the Pound Sterling (£). 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

Under Financial Reporting Standard 102, the company is exempt from the requirement to prepare a cash flow statement on the grounds that it qualifies as a small company.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)


2.8
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Property improvements
-
10%
straight line
Plant and machinery
-
20%
straight line
Motor vehicles
-
25%
reducing balance
Fixtures and fittings
-
20%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Valuation of investments

Investments comprise private vehicle number plates which are held at cost.

 
2.10

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for
obsolete and slow moving items.



 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 5

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.14

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 12 (2024 - 16).


4.


Tangible fixed assets





Leasehold Property improvements
Plant and machinery
Motor vehicles
Fixtures and fittings
Total

£
£
£
£
£



Cost or valuation


At 1 April 2024
485,625
130,434
243,496
73,983
933,538


Additions
-
360
55,095
10,424
65,879



At 31 March 2025

485,625
130,794
298,591
84,407
999,417



Depreciation


At 1 April 2024
114,355
39,582
93,536
31,272
278,745


Charge for the year on owned assets
48,562
26,123
57,784
16,881
149,350



At 31 March 2025

162,917
65,705
151,320
48,153
428,095



Net book value



At 31 March 2025
322,708
65,089
147,271
36,254
571,322



At 31 March 2024
371,270
90,853
149,960
42,711
654,794

Page 6

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

5.


Fixed asset investments





Unlisted investments

£



Cost or valuation


At 1 April 2024
237,554



At 31 March 2025
237,554





6.


Debtors

2025
2024
£
£


Trade debtors
588,304
885,067

Other debtors
477,761
425,223

Prepayments and accrued income
14,880
16,502

1,080,945
1,326,792



7.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
243,923
116,009

243,923
116,009


Page 7

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

8.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank loans
11,200
11,200

Trade creditors
1,700,945
1,062,147

Corporation tax
81,517
202,957

Other taxation and social security
23,972
86,380

Obligations under finance lease and hire purchase contracts
75,638
63,488

Other creditors
136,206
336,752

Accruals and deferred income
8,000
158,000

2,037,478
1,920,924



9.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
2,133
12,311

Net obligations under finance leases and hire purchase contracts
139,404
177,587

141,537
189,898


Page 8

 
AMG PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

10.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Bank loans
11,200
11,200


11,200
11,200

Amounts falling due 1-2 years

Bank loans
2,133
11,200


2,133
11,200

Amounts falling due 2-5 years

Bank loans
-
1,111


-
1,111


13,333
23,511


 
Page 9